HER2 Breast Cancer

Ron Bose, MD, PhD, discusses the rationale for a trial of neratinib plus alpelisib for patients with HER2-positive breast cancer.

Metastatic triple-negative breast cancer appears to derive clinical benefit from sacituzumab govitecan-hziy overtime, regardless of patients’ HER2 expression, according to a post hoc analysis of the phase 3 ASCENT trial.

Survival rates for patients with different subtypes of early breast cancer who had a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel are promising.

Breakthrough therapy designation has been granted to trastuzumab deruxtecan by the FDA for patients with unresectable or metastatic HER2-low breast cancer.

Ron Bose, MD, PhD, discusses the challenge of drug resistance due to mutations for patients with HER2-positive breast cancer.

Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.

Significant survival improvement has been shown with trastuzumab deruxtecan in patients with HER2-low breast cancer treated in the DESTINY-Breast04 clinical trial.

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the KAMILLA trial and the benefit of trastuzumab emtansine.

In an interview with Targeted Oncology, Ron Bose, MD, MPH, discussed HER2 drug resistance, its impact on treatment, and how new research may help in the future.

The FDA has accepted a supplement biologics license application for fam-trastuzumab deruxtecan-nxki and granted it priority review for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

HER2 mutations are a major clinical biomarker in breast cancer. However, overcoming drug resistance remains a key clinical obstacle.

Based on updated findings from the phase 2 SUMMIT trial, a neratinib triplet and neratinib doublet can induce responses in patients with HER2-positive breast cancer.

Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.

Updated data from the PHOEBE trial show that pyrotinib plus capecitabine improved overall survival in patients with HER2-positive breast cancer compared with lapatinib plus capecitabine.

Adding zanidatamab to chemotherapy may result in positive efficacy and safety outcomes in patients with HER2-positive breast cancer.

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.

In an interview with Targeted Oncology, lead author Xichun Hu, MD, PhD, discussed A166 and its impact on HER2-positive breast cancer.